Marja-Liisa Dahl

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Marja-Liisa Dahl är professor i klinisk farmakologi vid institutionen för laboratoriemedicin, avdelningen för klinisk farmakolog vid Karolinska Institutet sedan 2012. Hon är också funktionsområdeschef vid medicinsk enhet klinisk farmakologi, Karolinska Universitetssjukhuset.

Artiklar

Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025;91(2):464-478
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study
Soeria-Atmadja S; Amuge P; Nanzigu S; Bbuye D; Eriksen J; Rubin J; Kekitiinwa A; Obua C; Dahl M-L; Bergstrand MP; Pohanka A; Gustafsson LL; Naver L
Article: INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING. 2024;19(1):2292826
Lived experiences of closeness to a person using Anabolic androgenic steroids a next of kin perspective
Borjesson A; Ekebergh M; Dahl M-L; Ekstrom L; Lehtihet M; Vicente V
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(11):2823-2836
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania
Mugusi S; Mnkugwe RH; Sanga AA; Salahuddin A; Barclay V; Shayo G; Dahl M-L; Aklillu E
Article: SCIENTIFIC REPORTS. 2024;14(1):11730
CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children
Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl M-L; Aklillu E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2023;79(9):1261-1269
Medicines postpartum in Sweden and coverage in Janusmed Breastfeeding
Asplund AB; Skold PD; Lind LK; Cesta CE; Dahl ML; Jonsson EW; Andersson ML
Article: DRUGS & AGING. 2023;40(4):369-376
Pharmacological Risk Assessment Among Older Patients with Polypharmacy Using the Clinical Decision Support System Janusmed Risk Profile: A Cross-Sectional Register Study
Petersson L; Schoergenhofer C; Askfors Y; Justad H; Dahl M-L; Andersson MLL
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;130(4):492-500
Plasma concentrations of methylphenidate enantiomers in adults with ADHD and substance use disorder, with focus on high doses and relationship to carboxylesterase activity
Arvidsson M; Franck J; Ackehed G; Bergstrand MP; Ekstrom L; Rosenborg S; Dahl M-L
Article: FRONTIERS IN REPRODUCTIVE HEALTH. 2021;3:787954
A Summary of Online Enquiries Submitted to Anti-doping Hotline 2005-2018
Ekstrom L; Brostrom S; Dahl M-L; Borjesson A
Article: FRONTIERS IN SPORTS AND ACTIVE LIVING. 2021;3:656413
Women's Experiences of Using Anabolic Androgenic Steroids
Boerjesson A; Ekebergh M; Dahl M-L; Ekstroem L; Lehtihet M; Vicente V
Article: SCIENTIFIC REPORTS. 2021;11(1):5796
CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study
Dahl M-L; Leander K; Vikstrom M; Frumerie C; Nordenmalm S; Moller J; Soderberg-Lofdal K
Article: INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING. 2021;16(1):1927490
Men′s experiences of using anabolic androgenic steroids
Borjesson A; Ekebergh M; Dahl M-L; Ekstrom L; Lehtihet M; Vicente V
Article: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2020;13(9):925-934
Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet
Hoffmann M; Vander Stichele R; Bates DW; Bjorklund J; Alexander S; Andersson ML; Auraaen A; Bennie M; Dahl M-L; Eiermann B; Hackl W; Hammar T; Hjemdahl P; Koch S; Kunnamo I; Le Louet H; Panagiotis P; Raego L; Spedding M; Seidling HM; Demner-Fushman D; Gustafsson LL
Article: MEDICINA-LITHUANIA. 2020;56(6):E265-265
Male Anabolic Androgenic Steroid Users with Personality Disorders Report More Aggressive Feelings, Suicidal Thoughts, and Criminality
Borjesson A; Moller C; Hagelin A; Vicente V; Rane A; Lehtihet M; Dahl M-L; Garevik N; Ekstrom L
Article: DRUG TESTING AND ANALYSIS. 2020;12(4):514-523
Studies of athlete biological passport biomarkers and clinical parameters in male and female users of anabolic androgenic steroids and other doping agents
Borjesson A; Lehtihet M; Andersson A; Dahl M-L; Vicente V; Ericsson M; Ekstrom L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2020;76(2):229-237
Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers
Arvidsson M; Dahl M-L; Beck O; Ackehed G; Nordin K; Rosenborg S
Article: NORDIC JOURNAL OF PSYCHIATRY. 2019;73(2):118-124
Methylphenidate effects on processing speed in a clinical sample of adults with ADHD and substance use disorder: a pilot study
Arvidsson M; Dahl M-L; Franck J; Wiig EH; Nielsen NP
Article: DRUG TESTING AND ANALYSIS. 2019;11(1):27-32
Drug abuse screening with exhaled breath and oral fluid in adults with substance use disorder
Arvidsson M; Ullah S; Franck J; Dahl M-L; Beck O
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(6):843-851
Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium
Eichelbaum M; Dahl M-L; Sjoqvist F
Article: CNS DRUGS. 2017;31(11):991-997
Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study
Smith RL; Haslemo T; Andreassen OA; Eliasson E; Dahl M-L; Spigset O; Molden E
Article: PLOS ONE. 2017;12(9):e0181316
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
Soeria-Atmadja S; Osterberg E; Gustafsson LL; Dahl M-L; Eriksen J; Rubin J; Naver L
Article: SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY. 2016;11:11
Recruitment to doping and help-seeking behavior of eight female AAS users
Borjesson A; Garevik N; Dahl M-L; Rane A; Ekstrom L
Article: CURRENT DRUG METABOLISM. 2016;17(3):227-236
Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Ragia G; Dahl M-L; Manolopoulos VG
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2015;71(4):433-439
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy
Chang M; Soderberg MM; Scordo MG; Tybring G; Dahl M-L
Article: JOURNAL OF PSYCHIATRY & NEUROSCIENCE. 2015;40(2):126-133
Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia - significance for activation of the kynurenine pathway
Schwieler L; Larsson MK; Skogh E; Kegel ME; Orhan F; Abdelmoaty S; Finn A; Bhat M; Samuelsson M; Lundberg K; Dahl M-L; Sellgren C; Schuppe-Koistinen I; Svensson CI; Erhardt S; Engberg G
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2015;71(1):117-124
Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives
Hedenmalm K; Granberg AG; Dahl M-L
Article: PHARMACOGENETICS AND GENOMICS. 2014;24(5):272-275
No influence of CYP3A43 rs472660G>A on steady-state serum olanzapine concentrations in White psychiatric patients
Soderberg MM; Molden E; Dahl M-L
Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2014;7:15-22
Imbalanced kynurenine pathway in schizophrenia.
Kegel ME; Bhat M; Skogh E; Samuelsson M; Lundberg K; Dahl M-L; Sellgren C; Schwieler L; Engberg G; Schuppe-Koistinen I; Erhardt S
Article: PHARMACOGENOMICS JOURNAL. 2013;13(6):544-550
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients
Soderberg MM; Haslemo T; Molden E; Dahl M-L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:S25-S32
Therapeutic drug monitoring for tomorrow
Eliasson E; Lindh JD; Malmstrom RE; Beck O; Dahl M-L
Article: PHARMACOGENETICS AND GENOMICS. 2013;23(5):279-285
Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure
Soderberg MM; Haslemo T; Molden E; Dahl M-L
Article: PHARMACOGENOMICS. 2013;14(6):613-622
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
Margolin S; Lindh JD; Thoren L; Xie H; Koukel L; Dahl M-L; Eliasson E
Article: SCHIZOPHRENIA BULLETIN. 2012;38(3):426-432
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm KR; Skogh E; Olsson SK; Dahl M-L; Holtze M; Engberg G; Samuelsson M; Erhardt S
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2011;67(12):1223-1229
Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting
Gokalp O; Gunes A; Cam H; Cure E; Aydin O; Tamer MN; Scordo MG; Dahl M-L
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2011;31(1):4-9
High Correlation Between Serum and Cerebrospinal Fluid Olanzapine Concentrations in Patients With Schizophrenia or Schizoaffective Disorder Medicating With Oral Olanzapine as the Only Antipsychotic Drug
Skogh E; Sjodin I; Josefsson M; Dahl M-L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2011;67(1):47-54
Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl M-L; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Article: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. 2010;53(3):576-582
Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid
Josefsson M; Roman M; Skogh E; Dahl M-L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2010;87(6):727-734
A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age
Hamberg A-K; Wadelius M; Lindh JD; Dahl ML; Padrini R; Deloukas P; Rane A; Jonsson EN
Article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 2010;25(4):347-352
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients
Melkersson KI; Gunes A; Dahl M-L
Article: PHARMACEUTICALS. 2010;3(4):782-794
Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
Dahl M-L; Gunes A
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2010;19(3):223-231
Muscle toxicity with statins
Hedenmalm K; Alvan G; Ohagen P; Dahl M-L
Article: SCANDINAVIAN JOURNAL OF PAIN. 2010;1(1):24-33
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl M-L; Kalso EA
Article: PHARMACOGENOMICS. 2009;10(9):1447-1455
Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis.
Mao M; Matimba A; Scordo MG; Gunes A; Zengil H; Yasui-Furukori N; Masimirembwa C; Dahl M-L
Article: PHARMACOGENOMICS. 2009;10(5):769-778
Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl M-L
Article: AMINO ACIDS. 2009;36(3):529-533
Taurine in plasma and CSF: a study in healthy male volunteers.
Samuelsson M; Dahl M-L; Gupta RC; Nordin C
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2009;29(1):65-68
Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine
Gunes A; Melkersson KI; Scordo MG; Dahl M-L
Article: CLINICAL PHARMACOKINETICS. 2009;48(1):63-70
Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
Lind A-B; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl M-L
Article: JACC-CARDIOVASCULAR INTERVENTIONS. 2008;1(6):620-627
The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl M-L
Article: JACC-CARDIOVASCULAR INTERVENTIONS. 2008;1(6):612-619
The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl M-L
Article: THERAPEUTIC DRUG MONITORING. 2008;30(5):628-633
ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl M-L; Scordo MG
Article: JOURNAL OF PSYCHIATRIC RESEARCH. 2008;42(11):884-893
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
Alenius M; Wadelius M; Dahl M-L; Hartvig P; Lindström L; Hammarlund-Udenaes M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2008;84(1):52-62
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Magnusson MO; Dahl M-L; Cederberg J; Karlsson MO; Sandström R
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(5):477-482
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.
Gunes A; Dahl M-L; Spina E; Scordo MG
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2008;25(2):151-159
Incidence and predictors of severe bleeding during warfarin treatment
Lindh JD; Holm L; Dahl M-L; Alfredsson L; Rane A
Article: THERAPEUTIC DRUG MONITORING. 2007;29(4):417-422
Depot haloperidol treatment in outpatients with schizophrenia on monotherapy:: Impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome
Panagiotidis G; Arthur HW; Lindh JD; Dahl M-L; Sjoqvist F
Article: JOURNAL OF CLINICAL PSYCHIATRY. 2007;68(5):697-704
Impact of CYP1A2 and CYO2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients
Melkersson KI; Scordo MG; Gunes A; Dahl M-L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2007;81(4):529-538
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.
Hamberg A-K; Dahl M-L; Barban M; Scordo MG; Wadelius M; Pengo V; Padrini R; Jonsson EN
Article: PSYCHOPHARMACOLOGY. 2007;190(4):479-484
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl M-L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2006;62(9):721-726
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.
Varsaldi F; Miglio G; Scordo MG; Dahl M-L; Villa LM; Biolcati A; Lombardi G
Article: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL. 2006;21(3):151-158
Mirtazapine naturalistic depression study (in Sweden)--MINDS(S): clinical efficacy and safety.
Wålinder J; Prochazka J; Odén A; Sjödin I; Dahl M-L; Ahlner J; Bengtsson F
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2006;26(2):192-197
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
Hedenmalm K; Güzey C; Dahl M-L; Yue Q-Y; Spigset O
Article: PHARMACOLOGICAL RESEARCH. 2006;53(2):162-165
No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.
Scordo MG; Dahl M-L; Spina E; Cordici F; Arena MG
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(1):103-113
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2005;97(5):296-301
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2004;60(5):337-342
CYP2C9 genetic variants and losartan oxidation in a Turkish population
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Article: JOURNAL OF ANALYTICAL TOXICOLOGY. 2004;28(2):94-104
Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19
Holmgren P; Carlsson B; Zackrisson AL; Lindblom B; Dahl ML; Scordo MG; Druid H; Ahlner J
Article: NORDIC JOURNAL OF PSYCHIATRY. 2004;58(1):61-64
CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum.
Josefsson A; Sydsjö G; Berg G; Dahl M-L; Wadelius M; Nordin C
Article: PSYCHOPHARMACOLOGY. 2003;170(2):157-166
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses
Melkersson KI; Dahl ML
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2003;13(5):333-335
CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype
Nordin C; Dahl ML; Eklundh T; Eriksson M; Sjöberg S
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(5-6):401-406
Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(3):221-225
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
Dorado P; Berecz R; Norberto MJ; Yasar Ü; Dahl ML; LLerena A
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2003;55(6):630-634
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(2):103-109
Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
Griskevicius L; Yasar Ü; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(1):45-50
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; Llerena A
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;72(6):702-710
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Article: THERAPEUTIC DRUG MONITORING. 2002;24(4):518-526
Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting
Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2002;22(4):406-413
Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting.
Reis M; Olsson G; Carlsson B; Lundmark J; Dahl M-L; Wålinder J; Ahlner J; Bengtsson F
Article: PSYCHOPHARMACOLOGY. 2002;162(1):67-73
Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Article: PAIN. 2002;96(3):261-267
Analgesic effects of dextromethorphan and morphine in patients with chronic pain.
Heiskanen T; Härtel B; Dahl M-L; Seppälä T; Kalso E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(3):141-152
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Article: PHARMACOGENOMICS JOURNAL. 2002;2(2):111-116
Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes.
Finnström N; Ask B; Dahl M-L; Gadd M; Rane A
Article: PHARMACOGENETICS AND GENOMICS. 2001;11(9):815-824
Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter
Hedberg JJ; Backlund M; Strömberg P; Lönn SS; Dahl ML; Ingelman-Sundberg M; Höög JO
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2001;57(10):729-735
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
Yasar Ü; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Article: THERAPEUTIC DRUG MONITORING. 2001;23(6):658-664
Enantioselective analysis of citalopram and metabolites in adolescents
Carlsson B; Olsson G; Reis M; Wålinder J; Nordin C; Lundmark J; Scordo MG; Dahl ML; Bengtsson F; Ahlner J
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2001;52(4):447-450
Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2001;52(3):265-271
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
Article: DRUG METABOLISM AND DISPOSITION. 2001;29(7):1051-1056
Role of CYP2C9 polymorphism in losartan oxidation
Yasar Ü; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2000;56(9-10):679-683
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Article: GASTROENTEROLOGY. 2000;119(3):670-676
Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Article: THERAPEUTIC DRUG MONITORING. 2000;22(4):409-417
Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benítez J; Bertilsson L
Article: THERAPEUTIC DRUG MONITORING. 2000;22(1):114-117
Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics
Dahl ML; Sjöqvist F
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2000;49(2):180-184
Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
Dalén P; Dahl ML; Andersson K; Bertilsson L
Article: NORDIC JOURNAL OF PSYCHIATRY. 2000;54(1):61-65
Psychotropic drug use in non-psychiatric departments of three European university hospitals
Llerena A; Kiivet RA; Dahl ML; Vega JS; Rootslane L; Wettermark B
Article: PSYCHOPHARMACOLOGY. 1999;147(3):300-305
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(6):707-714
Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype
Wennerholm A; Johansson I; Massele AY; Jande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(6):697-706
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(5):657-660
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;254(3):628-631
Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population
Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjoqvist F
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 1998;1(2):95-101
D₂- and 5-HT₂ receptor occupancy in high-dose neuroleptic-treated patients
Nyberg S; Dencker SJ; Malm U; Dahl ML; Svenson JO; Halldin C; Naskashima Y; Farde L
Article: FEBS LETTERS. 1998;438(3):201-205
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
Oscarson M; Gullstén H; Rautio A; Bernal ML; Sinues B; Dahl ML; Stengård JH; Pelkonen O; Raunio H; Ingelman-Sundberg M
Article: DRUG METABOLISM AND DISPOSITION. 1998;26(11):1096-1101
1- and 3-hydroxylations, in addition to 4-hydroxylation, of debrisoquine are catalyzed by cytochrome P450 2D6 in humans
Eiermann B; Edlund PO; Tjernberg A; Dalén P; Dahl ML; Bertilsson L
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1998;33(10):1034-1038
CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection
Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):402-411
CYP2D6 polymorphism is not crucial for the disposition of selegiline
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):391-401
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):384-390
Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1998;54(6):479-481
CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
Yamada H; Dahl ML; Lannfelt L; Viitanen M; Winblad B; Sjöqvist F
Article: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. 1998;12(3):204-207
No association between familial Alzheimer disease and cytochrome P450 polymorphisms
Yamada H; Dahl ML; Viitanen M; Winblad B; Sjöqvist F; Lannfelt L
Article: PSYCHIATRIC GENETICS. 1998;8(1):25-28
Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia
Jonsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 1998;30(3):277-280
Antibiotic use in 3 European university hospitals
Kiivet RA; Dahl ML; Llerena A; Maimets M; Wettermark B; Berecz R
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1997;53(3-4):257-260
Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1997;17(6):467-471
The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients
Mihara K; Otani K; Tybring G; Dahl ML; Bertilsson L; Kaneko S
Article: ACTA PSYCHIATRICA SCANDINAVICA. 1997;96(5):379-384
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Article: THERAPEUTIC DRUG MONITORING. 1997;19(5):543-544
Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.
Dalén P; Frengell C; Dahl ML; Sjöqvist F
Article: LANCET. 1997;350(9070):29-30
Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Nordin C; Dahl ML; Eriksson M; Sjoberg S
Article: MOLECULAR PHARMACOLOGY. 1997;51(3):370-376
Genetic polymorphism of human CYP2E1: Characterization of two variant alleles
Hu Y; Oscarson M; Johansson I; Yue QY; Dahl ML; Tabone M; Arinco S; Albano E; IngelmanSundberg M
Article: CLINICAL DRUG INVESTIGATION. 1997;13(1):37-46
In vitro and in vivo studies on the disposition of mirtazapine in humans
Dahl ML; Voortman G; Alm C; Elwin CE; Delbressine L; Vos R; Bogaards JJP; Bertilsson L
Article: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 1997;25(1):24-32
Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients
Syvalahti EKG; Taiminen T; Saarijarvi S; Lehto H; Niemi H; Ahola V; Dahl ML; Salokangas RKR
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(6):547-551
CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Article: JOURNAL OF INTERNAL MEDICINE. 1996;240(5):311-314
Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: A causal relationship?
Gustafsson LL; Eriksson LS; Dahl ML; Eleborg L; Ericzon BG; Nyberg A
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(5):441-447
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
Roh HK; Dahl ML; Johansson I; IngelmanSundberg M; Cha YN; Bertilsson L
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(4):351-355
PCR-based genotyping for duplicated and deleted CYP2D6 genes
Johansson I; Lundqvist E; Dahl ML; IngelmanSundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1996;60(2):183-190
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodriguez I; Bertilsson L
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 1996;78(5):303-307
Debrisoquin and S-Mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population
Marandi T; Dahl ML; Kiivet RA; Rago L; Sjoqvist F
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1996;59(4):423-428
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol
Jerling M; Dahl ML; AbergWistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjoqvist F
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1996;41(4):344-346
Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes
Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA
Article: PSYCHOPHARMACOLOGY. 1996;123(4):315-319
Steady state plasma levels of nortriptyline and its 1.0-hydroxy metabolite: Relationship to the CYP2D6 genotype
Dahl ML; Bertilsson L; Nordin C
Article: PHARMACOGENETICS AND GENOMICS. 1995;5(6):358-363
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
Chang M; Dahl ML; Tybring G; Gotharson E; Bertilsson L
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1995;40(5):467-476
PATTERNS OF DRUG-TREATMENT OF SCHIZOPHRENIC-PATIENTS IN ESTONIA, SPAIN AND SWEDEN
KIIVET RA; LLERENA A; DAHL ML; ROOTSLANE L; VEGA JS; EKLUNDH T; SJOQVIST F
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1995;274(1):516-520
ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS
DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
Article: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 1995;15(3):211-216
POLYMORPHIC DRUG-METABOLISM IN SCHIZOPHRENIC-PATIENTS WITH TARDIVE-DYSKINESIA
ARTHUR H; DAHL ML; SIWERS B; SJOQVIST F
Article: PHARMACOGENETICS AND GENOMICS. 1995;5(3):159-164
GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
DAHL ML; YUE QY; ROH HK; JOHANSSON I; SAWE J; SJOQVIST F; BERTILSSON L
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1995;39(5):511-518
INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19
CHANG M; TYBRING G; DAHL ML; GOTHARSON E; SAGAR M; SEENSALU R; BERTILSSON L
Visa fler

Alla övriga publikationer

Review: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY. 2021;22(8):561-628
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants
Eap CB; Grunder G; Baumann P; Ansermot N; Conca A; Corruble E; Crettol S; Dahl ML; de Leon J; Greiner C; Howes O; Kim E; Lanzenberger R; Meyer JH; Moessner R; Mulder H; Muller DJ; Reis M; Riederer P; Ruhe HG; Spigset O; Spina E; Stegman B; Steimer W; Stingl J; Suzen S; Uchida H; Unterecker S; Vandenberghe F; Hiemke C
Other: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(6):1127-1128
Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology
Dahl M-L; Bergman U; Bertilsson L; Eliasson E; Gustafsson LL; Panagiotidis G; Rane A
Letter: SCHIZOPHRENIA RESEARCH. 2018;199:438-441
Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients
Checa A; Malmqvist A; Flyckt L; Schwieler L; Samuelsson M; Skogh E; Cervenka S; Dahl M-L; Piehl F; Erhardt S; Wheelock CE
Review: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(8):435-442
An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21^st Century Science and Ethics"
Dove ES; Barlas IO; Birch K; Boehme C; Borda-Rodriguez A; Byne WM; Chaverneff F; Coskun Y; Dahl M-L; Dereli T; Diwakar S; Elbeyli L; Endrenyi L; Eroglu-Kesim B; Ferguson LR; Gungor K; Gursoy U; Hekim N; Huzair F; Kaushik K; Kickbusch I; Kiroglu O; Kolker E; Kononen E; Lin B; Llerena A; Malhan F; Nair B; Patrinos GP; Sardas S; Sert O; Srivastava S; Steuten LMG; Toraman C; Vayena E; Wang W; Warnich L; Ozdemir V
Letter: CLINICAL PHARMACOKINETICS. 2015;54(3):321
Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors' Reply
Lindh JD; Chang M; Tybring G; Dahl M-L
Review: CLINICAL PHARMACOKINETICS. 2014;53(9):801-811
Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis
Chang M; Tybring G; Dahl M-L; Lindh JD
Review: PHARMACOGENOMICS. 2013;14(11):1319-1336
Pharmacogenetics of olanzapine metabolism
Soderberg MM; Dahl M-L
Letter: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. 2012;32(2):287-289
Interindividual Variation in Olanzapine Concentration Influenced by UGT1A4 L48V Polymorphism in Serum and Upstream FMO Polymorphisms in Cerebrospinal Fluid
Mao M; Skogh E; Scordo MG; Dahl M-L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S469
Olanzapine in serum and cerebrospinal fluid in patients with schizophrenia or schizoaffective disorder
Skogh E; Sjodin I; Josefsson M; Dahl ML
Review: PHARMACOGENOMICS. 2008;9(5):625-637
Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.
Gunes A; Dahl M-L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:s531-s532
Impact of CYP3A4 polymorphisms on donepezil plasma levels and therapeutic outcome
Scordo MG; Villa LM; Miglio G; Lombardi G; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S452-S453
Association between a 5HT2C receptor haplotype and metabolic abnormalities in patients treated with olanzapine
Gunes A; Melkersson KI; Scordo MG; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:s434
Genetic polymorphisms as indicators of response to antipsychotics
Alenius M; Hammarlund-Udenaes M; Wadelius M; Dahl ML; Hartvig P; Lindstroem L
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S307-S308
Taurine in plasma and CSF - a study in healthy male volunteers
Nordin C; Dahl ML; Gupta RC; Samuelsson M
Review: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. 2007;2007(1):CD002216
Therapeutic monitoring of antiepileptic drugs for epilepsy
Tomson T; Dahl ML; Kimland E
Review: PHARMACOGENOMICS. 2006;7(8):1199-1210
Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?
Ozdemir V; Gunes A; Dahl M-L; Scordo MG; Williams-Jones B; Someya T
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s478-s479
Impact of Apo-E genotype on the response to donepezil therapy in patients with Alzheimer's disease
Scordo MG; Varsaldi F; Arena MG; Villa ML; Lombardi G; Cordici E; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:s24
Dopamine D2 and D3 receptor gene polymorphisms and clinical outcome of risperidone therapy in schizophrenic patients
Gunes A; Scordo MG; Spina E; Dahl ML
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15:s61-s62
Clinical impact of CYP2D6 polymorphism in patients with Alzheimer's disease in therapy with donepezil
Scordo MG; Varsaldi F; Miglio G; Villa ML; Biolcati A; Dahl ML; Lombardi G
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2004;14:S293-S294
Impact of CYP1A2 and 2D6 genetic polymorphisms on clozapine and olanzapine metabolism at steady-state
Scordo MG; Gunes A; Melkersson KI; Dahl ML
Review: PSYCHOPHARMACOLOGY. 2004;175(1):1-6
Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism
Melkersson KI; Dahl ML; Hulting AL
Review: DRUGS. 2004;64(7):701-723
Adverse metabolic effects associated with atypical antipsychotics - Literature review and clinical implications
Melkersson K; Dahl ML
Letter: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(2):183-185
Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
Yasar Ü; Dahl ML; Christensen M; Eliasson E
Letter: CARCINOGENESIS. 2002;23(4):665
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk
Yasar Ü; Eliasson E; Dahl ML
Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;53(2):111-122
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson L; Dahl ML; Dalén P; Al-Shurbaji A
Review: CLINICAL PHARMACOKINETICS. 2002;41(7):453-470
Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
Dahl M-L
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(1):89-98
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype
Yasar Ü; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Review: ACTA PSYCHIATRICA SCANDINAVICA. 2001;104(3):173-192
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:: a first step towards subpopulation-specific dosages
Kirchheiner J; Brosen K; Dahl ML; Gram LF; Kasper S; Roots I; Sjöqvist F; Spina E; Brockmöller J
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2001;29(4):580-585
Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation
Alvan G; Bertilsson L; Dahl ML; Ingelman-Sundberg M; Sjöqvist F
Review: CLINICAL PHARMACOKINETICS. 2001;40(11):869-877
Quantitative pharmacogenetics of nortriptyline -: A novel approach
Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
Meeting abstract: GASTROENTEROLOGY. 1998;114(4):A273
The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H-pylori infection in patients with acid related disease.
Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;63(4):444-452
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CΥP2D6 genes
Dalén P; Dahl ML; Ruiz MLB; Nordin J; Bertilsson L
Letter: BRITISH JOURNAL OF PSYCHIATRY. 1997;171:391-392
Paroxetine withdrawal syndrome in a neonate.
Dahl ML; Olhager E; Ahlner J
Letter: JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 1997;45(8):1029-1031
Traffic dangerous drugs are often found in fatally injured older male drivers
Johansson K; Bryding G; Dahl ML; Holmgren P; Viitanen M
Published conference paper: ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT. 1997;96:14-21
Pharmacogenetics of antidepressants: Clinical aspects
Bertilsson L; Dahl ML; Tybring G
Review: CNS DRUGS. 1996;5(3):200-223
Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders
Bertilsson L; Dahl ML
Other: PSYCHOPHARMACOLOGY. 1995;119(3):345-348
A PET STUDY OF D-2, AND 5-HT2, RECEPTOR OCCUPANCY INDUCED BY RISPERIDONE IN POOR METABOLIZERS OF DEBRISOQUIN AND RISPERIDONE
NYBERG S; DAHL ML; HALLDIN C
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(2):173-178
D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE
NYBERG S; FARDE L; HALLDIN C; DAHL ML; BERTILSSON L
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI